

Towards de-escalation of axillary management after neoadjuvant chemotherapy in breast cancer

Citation for published version (APA):

Simons, J. M. (2019). *Towards de-escalation of axillary management after neoadjuvant chemotherapy in breast cancer*. ProefschriftMaken. <https://doi.org/10.26481/dis.20191218js>

Document status and date:

Published: 01/01/2019

DOI:

[10.26481/dis.20191218js](https://doi.org/10.26481/dis.20191218js)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Stellingen behorende bij het proefschrift

**Towards de-escalation of axillary management
after neoadjuvant chemotherapy in breast cancer**

Janine Simons, 18 december 2019

1. The combination of sentinel lymph node biopsy with the MARI-procedure should be the preferred staging method when omission of axillary lymph node dissection is considered. (This thesis)
2. A pathologic complete response of the breast may guide omission of axillary surgery in selected clinically node negative breast cancer patients. (This thesis)
3. The decision on how to manage the axilla after chemotherapy in node positive breast cancer is mainly institution- and sometimes even specialist-dependent. (This thesis)
4. In node positive breast cancer, sentinel lymph node biopsy is only sufficiently accurate when ≥ 3 sentinel nodes are removed and is therefore not feasible in clinical practice. (This thesis)
5. Conducting studies where subtype-specific breast cancers are treated with specific regimens are more likely to show improvements and help us understand which patients will benefit from additional therapies. (Dr KK Hunt)
6. The biggest challenge in immunotherapy now is figuring out why an immune drug works in some patients and not in others, or in some tumors and not in others; to do that we need to go back to basic science. (Dr JP Allison)
7. Niet alleen de behandeling van borstkanker verdient personalisatie, ook de follow-up.
8. Al heb ik er zelf geen voordeel aan, ik wil deelnemen voor toekomstige patiënten, zodat voor hen de zorg mogelijk beter is. (studie-patiënte)
9. Het is zoals het is. (JvdL)
10. When I had all the answers, the questions changed. (Paulo Coelho)
11. Vita brevis, ars longa. (Hippocrates)